U.K.’s National Institute for Health and Care Excellence has four drugs in its Highly Specialised Technology process.
Below are the drugs and the conditions for which they would treat:
- Inotersen for hereditary transthyretin-related amyloidosis;
- Patisiran for hereditary transthyretin-related amyloidosis;
- Volanesorsen for familial chylomicronaemia syndrome (FCS); and
- KRN23 for X- linked hypophosphataemia.
Ionis Pharmaceuticals’ inotersen is up for review against its close rival, Alnylam’s patisiran, according to a pharmaphorum report. Both drugs are geared toward similar patient populations.
To read more about the drugs on pharmaphorum, click here.
